June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Full-Thickness Macular Hole Closure with Topical Therapy
Author Affiliations & Notes
  • Jessie Wang
    Ophthalmology and Visual Science, The University of Chicago Medicine, Chicago, Illinois, United States
  • Jason Xiao
    Ophthalmology and Visual Science, The University of Chicago Medicine, Chicago, Illinois, United States
  • Sarah Rodriguez
    Ophthalmology and Visual Science, The University of Chicago Medicine, Chicago, Illinois, United States
  • Dimitra Skondra
    Ophthalmology and Visual Science, The University of Chicago Medicine, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Jessie Wang None; Jason Xiao None; Sarah Rodriguez None; Dimitra Skondra None
  • Footnotes
    Support  Illinois Society for the Prevention of Blindness (ISPB) Research grant
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3654. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessie Wang, Jason Xiao, Sarah Rodriguez, Dimitra Skondra; Full-Thickness Macular Hole Closure with Topical Therapy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3654.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Full-thickness macular holes (FTMHs) are classically treated with pars plana vitrectomy (PPV), but topical steroid, carbonic anhydrase inhibitor (CAI), and nonsteroidal anti-inflammatory (NSAID) have recently been proposed as a less invasive and more cost-effective therapeutic option. This retrospective case series examines the efficacy of topical therapy in the treatment of FTMH, and identifies clinical characteristics associated with successful closure.

Methods : Retrospective case series of FTMHs diagnosed and treated from 2017-22. Logistic and linear regression models were used to evaluate factors associated with hole closure and final best corrected logMar visual acuity (BCVA), respectively.

Results : Of 168 patients with FTMHs, 71 patients were started on combination therapy with steroid, CAI, and NSAID drops. 49 patients (avg 67yrs, 59% women) were included in the analysis; 22 were excluded due to poor follow-up. 7/49 were secondary post-PPV holes and 42/49 were idiopathic. 18/49 eyes (36.7%) achieved closure on topical therapy, of which 13 were idiopathic. In cases of successful closure, hole size was directly correlated with odds of closure: for every 10-micron decrease in size, odds of closure increased by 1.2x (p=0.001, CI 1.1-1.4). FTMHs <200um had a closure rate of 72.2% and a 31x odds of closure compared to those >300um (p=0.003, CI 3.17–307). FTMHs 200-300um had a closure rate of 27.8% and a 4.3x odds of closure compared to those >300um (p=0.211, CI 0.44–42.0). Finally, holes >300um had a closure rate of 0%. Average time to closure was 107.2 days (range 20-512 days), and was not correlated to hole size (p=0.217, CI -0.478–+1.938). However, the presence of vitreomacular traction (VMT) was found to be inversely related to successful closure (OR 6.1, CI 1.2-31.3, p=0.029). Finally, amongst patients who received primary PPV (N=18) versus those who underwent and failed a trial of drops before subsequently undergoing a PPV (N=12), there was no significant difference in final BCVA (p=0.856, CI -0.244–+0.292) through a mean follow-up of 60.6 weeks.

Conclusions : In the first study to-date to report the overall efficacy and clinical characteristics of successful macular hole closure with topical therapy, drops achieved an overall closure rate of 36.7%, with higher efficacy in smaller holes and those without VMT. Delaying PPV by first undergoing a trial of topical therapy did not negatively affect final BCVA.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×